Printer Friendly

Printed from http://www.researchandmarkets.com/reports/1447248

Kyowa Hakko Kirin Pharma, Inc. - Product Pipeline Review - Q4 2010

Description:
Kyowa Hakko Kirin Pharma, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Kyowa Hakko Kirin Pharma, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Kyowa Hakko Kirin Pharma, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Kyowa Hakko Kirin Pharma, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Kyowa Hakko Kirin Pharma, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Kyowa Hakko Kirin Pharma, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Kyowa Hakko Kirin Pharma, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Kyowa Hakko Kirin Pharma, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Kyowa Hakko Kirin Pharma, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Kyowa Hakko Kirin Pharma, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Kyowa Hakko Kirin Pharma, Inc. and identify potential opportunities in those areas.
 
Contents:

List of Tables
List of Figures
Kyowa Hakko Kirin Pharma, Inc. Snapshot
Kyowa Hakko Kirin Pharma, Inc. Overview
Key Information
Key Facts
Kyowa Hakko Kirin Pharma, Inc. – Research and Development Overview
Key Therapeutic Areas
Kyowa Hakko Kirin Pharma, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Kyowa Hakko Kirin Pharma, Inc. – Pipeline Products Glance
Kyowa Hakko Kirin Pharma, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Kyowa Hakko Kirin Pharma, Inc. – Drug Profiles
BIW-8962
Product Description
Mechanism of Action
R&D Progress
KRN125
Product Description
Mechanism of Action
R&D Progress
KRN330
Product Description
Mechanism of Action
R&D Progress
KRN330 + Irinotecan
Product Description
Mechanism of Action
R&D Progress
KW-2450 + Lapatinib + Letrozole
Product Description
Mechanism of Action
R&D Progress
KW-2478 + Bortezomib
Product Description
Mechanism of Action
R&D Progress
KW-2478
Product Description
Mechanism of Action
R&D Progress
KW-3357
Product Description
Mechanism of Action
R&D Progress
Kyowa Hakko Kirin Pharma, Inc. – Pipeline Analysis
Kyowa Hakko Kirin Pharma, Inc. – Pipeline Products by Therapeutic Class
Kyowa Hakko Kirin Pharma, Inc. Pipeline Products By Target
Kyowa Hakko Kirin Pharma, Inc. – Pipeline Products by Route of Administration
Kyowa Hakko Kirin Pharma, Inc. – Pipeline Products by Molecule Type
Kyowa Hakko Kirin Pharma, Inc. - Dormant Projects
Kyowa Hakko Kirin Pharma, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
KW-2449
KW-7158
Kyowa Hakko Kirin Pharma, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Apr 19, 2007: NESP (darbepoetin alfa) Injection Syringe Receives Approval
Apr 19, 2007: NESP (darbepoetin alfa) Injection Syringe Receives Approval
Sep 17, 2002: Kyowa Hakko’s Antiasthmatic Agent, KW-4490, Has Entered Early Phase II Clinical Studies In Europe
May 14, 2002: Kyowa Hakko Begins Clinical Phase II Trials In The U.S. And Europe Of KW-7158, A Treatment For Urinary Incontinence
Dec 06, 2001: Kyowa Hakko Initiates Phase II Clinical Studies Of KW-2170 For Cancer Treatment
Dec 06, 2001: Kyowa Hakko Initiates Phase II Clinical Studies Of KW-2170 For Cancer Treatment
Dec 06, 2001: Kyowa Hakko Initiates Phase II Clinical Studies Of KW-2170 For Cancer Treatment
Dec 06, 2001: Kyowa Hakko Initiates Phase II Clinical Studies Of KW-2170 For Cancer Treatment
Dec 06, 2001: Kyowa Hakko Initiates Phase II Clinical Studies Of KW-2170 For Cancer Treatment
Jun 06, 2001: Kyowa Hakko Bigins Phase II Trial Of KW-7158 For Urinary Incontinence
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
 
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/1447248

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Page 1 of 2
Printed Dec 17, 2014
10:07:25 PM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

Kyowa Hakko Kirin Pharma, Inc. - Product Pipeline Review - Q4 2010

Web Address

http://www.researchandmarkets.com/reports/1447248

Office Code

SCOI7T

 

Report Formats

Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User USD 500
Electronic (PDF) - Site License USD 1,000
Electronic (PDF) - Enterprisewide USD 1,500

Contact information

Please enter all the information below in block capitals.

Title:
Mr Mrs Dr Miss Ms Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2
Printed Dec 17, 2014
10:07:25 PM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
 
Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Pay by Wire Transfer:

Please transfer funds to:

Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
 

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)